임상 지침은 지속적으로 발전하는 작업: 과학의 속도로 나아가기

“The findings demonstrate that lower, more aggressive lowering of LDL-C with use of evolocumab improves outcomes in a high-risk primary prevention population and likely endorses early clinical adoption of lower LDL-C thresholds in patients like those in the VESALIUS-CV cohort.”